Generic Pharmaceutical Products was Ani Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $384.11M of $883.37M (43%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Generic Pharmaceutical Products | $210.12M | $269.45M | $301.00M | $384.11M | ||||||
| Sales Of Generic Pharmaceutical Products | — | — | — | — | ||||||
| Cortrophin Gel | $41.69M | $112.12M | $198.09M | $347.78M | ||||||
| Brands | $39.46M | $85.38M | $64.74M | $61.31M | ||||||
| Sales Of Established Brand Pharmaceutical Products, Royalties, & Other Pharmaceutical Services | — | — | — | — | ||||||
| Sales Of Established Brand Pharmaceutical Products | — | — | — | — | ||||||
| Sales Of Branded Pharmaceutical Products | — | — | — | — | ||||||
| Iluvien & Yutiq | — | — | $31.51M | $74.87M | ||||||
| Royalties & Other Pharmaceutical Services | $25.12M | $19.87M | $19.03M | $15.30M | ||||||
| Sales Of Contract Manufactured Products | — | — | — | — | ||||||
| Royalties From Licensing Agreements | — | — | — | — | ||||||
| Product Development Services | — | — | — | — | ||||||
| Other | — | — | — | — | ||||||
| Other Revenues | — | — | — | — | ||||||
| Total | $316.39M | $486.82M | $614.38M | $883.37M |
Ani Pharmaceuticals brought in $883.37M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 43.8% from $614.38M in fiscal 2024. Generic Pharmaceutical Products was the largest at $384.11M (43.5%), ahead of Cortrophin Gel at $347.78M (39.4%) and Iluvien & Yutiq at $74.87M (8.5%). The other two lines brought in $76.61M combined.
Compared with fiscal 2024, Iluvien & Yutiq grew fastest, up 137.6% to $74.87M, while Brands fell the most, down 5.3% to $61.31M.
Ani Pharmaceuticals began breaking out Iluvien & Yutiq in fiscal 2024, when it brought in $31.51M.
Rare Disease & Brands was Ani Pharmaceuticals’s largest segment in fiscal 2025, bringing in $483.93M of $883.37M (55%).
| Segment | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Generics & Other | $235.24M | $289.31M | $320.03M | $399.43M | ||||||
| Rare Disease & Brands | $81.15M | $197.50M | $294.34M | $483.93M | ||||||
| Generics, Established Brands & Other | — | — | — | — | ||||||
| United States | — | — | — | — | ||||||
| Canada | — | — | — | — | ||||||
| Total | $316.39M | $486.82M | $614.38M | $883.37M |
Ani Pharmaceuticals brought in $883.37M from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 43.8% from $614.38M in fiscal 2024. Rare Disease & Brands was the largest at $483.93M (54.8%), ahead of Generics & Other at $399.43M (45.2%).
Compared with fiscal 2024, Rare Disease & Brands grew 64.4% to $483.93M and Generics & Other grew 24.8% to $399.43M. From fiscal 2022 to 2025, combined revenue from these segments grew from $316.39M to $883.37M, a compound annual growth rate of 40.8%. Rare Disease & Brands' share of the total rose from 25.6% to 54.8%.
United States was Ani Pharmaceuticals’s largest region in fiscal 2025, bringing in $852.44M of $883.37M (96%).
| Geography | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| United States | $312.43M | $486.25M | $604.99M | $852.44M | ||||
| International | $3.96M | $565.00K | $9.39M | $30.92M | ||||
| Canada | — | — | — | — | ||||
| Total | $316.39M | $486.82M | $614.38M | $883.37M |
Ani Pharmaceuticals brought in $883.37M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 43.8% from $614.38M in fiscal 2024. United States was the largest at $852.44M (96.5%), ahead of International at $30.92M (3.5%).
Compared with fiscal 2024, International grew 229.4% to $30.92M and United States grew 40.9% to $852.44M. From fiscal 2022 to 2025, combined revenue from these regions grew from $316.39M to $883.37M, a compound annual growth rate of 40.8%. United States' share of the total fell from 98.7% to 96.5%.
Ani Pharmaceuticals (ANIP) reports its revenue by product and service, by segment and by geography. In fiscal 2025, Generic Pharmaceutical Products was its largest product and service line, bringing in $384.11M (43.5% of the total), followed by Cortrophin Gel at $347.78M (39.4%).
Generic Pharmaceutical Products was Ani Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $384.11M, or 43.5% of the $883.37M total across its five product and service lines.
Rare Disease & Brands was Ani Pharmaceuticals' largest segment in fiscal 2025, bringing in $483.93M, or 54.8% of the $883.37M total across its two segments.
United States was Ani Pharmaceuticals' largest region in fiscal 2025, bringing in $852.44M, or 96.5% of the $883.37M total across its two regions.
Among Ani Pharmaceuticals' product and service lines that make up at least 2% of revenue, Iluvien & Yutiq grew fastest in fiscal 2025, up 137.6% from $31.51M to $74.87M.
Every figure comes from Ani Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Ani Pharmaceuticals gives it, and years follow its fiscal calendar.
Ani Pharmaceuticals' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.